DDInter1432 DDInter1082
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Perphenazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Perphenazine {u} (Compound) resembles {v} (Compound) Propericiazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Perphenazine {u} (Compound) binds {v} (Gene) CYP2C18
Perphenazine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Perphenazine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Perphenazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Perphenazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Perphenazine {u} (Compound) causes {v} (Side Effect) Nocturnal confusion
Perphenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Perphenazine (Compound) resembles Triflupromazine (Compound)
Perphenazine (Compound) resembles Propericiazine (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Perphenazine (Compound) binds CYP2C18 (Gene)
Perphenazine (Compound) upregulates ST3GAL5 (Gene)
Perphenazine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Perphenazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Perphenazine (Compound) downregulates TXNDC9 (Gene)
Perphenazine (Compound) causes Nocturnal confusion (Side Effect)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate